Real-World practice patterns and adverse events of pegcetacoplan injection for Geographic Atrophy

Abstract

Purpose : To assess Real-World practice patterns and adverse events of pegcetacoplan injection for Geographic Atrophy (GA).

Methods : A retrospective consecutive case series was performed using a large consortium of retina practices across the US. Patients who underwent treatment with pegcetacoplan injection from February 17th 2023 to November 29th 2023 who had at least 28 days of follow-up were included.

Results : To date, a total of 5149 eyes have received 14,589 injections of pegcetacoplan across 3903 patients. The mean age is 82.6 years and 32.6% are male. The median visual acuity was 20/50 in eyes receiving treatment. Of the eyes receiving treatment, 45.8% of patients had 20/50 or better vision, 32.1% of patients had vision 20/60 to 20/150 and 22.1% of patients had 20/200 or worse vision. The average treatment interval was 45 days. 1247 patients received at least one bilateral same day pegcetacoplan injection during the study period. Five patients without a history of neovascular AMD developed CNV over the study period. There were 19 patients with any form of intraocular inflammation including one case of occlusive vasculitis (0.03% per patient), and 3 cases of endophthalmitis. There were 2 cases of retinal detachment.

Conclusions : Given recent approval of pegcetacoplan injection, our findings on practice patterns for its use and the resulting adverse events will be of great interest to retina specialists implementing this new therapy. Further investigation using this dataset is ongoing.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.